05-25 Beam Therapeutics Inc. Presents at RBC Capital Markets Global Healthcare Conference 2026, May-20-2026 10:30 AM
05-18 Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference GL
05-18 Beam Therapeutics Inc. Presents Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency At American Thoracic Society International Conference CI
05-13 Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference GL
05-12 Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026 GL
05-07 Beam Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-07 Earnings Flash (BEAM) Beam Therapeutics Inc. Reports Q1 Revenue $31.7M, vs. FactSet Est of $11.0M MT
05-07 Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates GL
04-02 Beam Therapeutics Insider Sold Shares Worth $1,128,315, According to a Recent SEC Filing MT
04-01 Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine GL
04-01 Beam Therapeutics Publishes Beacon Phase 1/2 Data for Risto-Cel in Patients with Sickle Cell Disease CI
03-25 Beam Therapeutics Inc. - Special Call
03-25 Beam Therapeutics Says It Advances BEAM-302 to Pivotal Stage With 60 mg Dose Selection MT
03-25 Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency CI
03-25 Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development GL
03-05 Beam Therapeutics Inc. Terminates License Agreement with Bio Palette Co., Ltd CI
02-25 RBC Capital Adjusts Beam Therapeutics Price Target to $26 From $22, Maintains Sector Perform - Speculative Risk Rating MT
02-24 Beam Therapeutics Inc., Q4 2025 Earnings Call, Feb 24, 2026
02-24 Beam Therapeutics Shares Rise After Swinging to Q4 Adjusted Earnings MT
02-24 Beam Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
02-24 Beam Therapeutics Inc. announced that it expects to receive $500 million in funding CI
02-24 Wedbush Raises Beam Therapeutics Price Target to $65 From $57, Maintains Outperform Rating MT
02-24 Beam Therapeutics Inc. Announces $500 Million Strategic Financing Facility with Sixth Street CI
02-24 Beam Therapeutics Secures Up to $500 Million Sixth Street Financing MT
02-24 Beam Therapeutics Swings to Q4 Adjusted Earnings, Revenue Rises -- Shares Up Pre-Bell MT
No results match your criteria
  1. Stock Market
  2. Stocks
  3. BEAM Stock
  4. News Beam Therapeutics Inc.
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!